David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.

Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata

Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions

Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football

Aditya Bagrodia describes three new drugs/studies in NMIBC.

Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.

Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.

David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.

Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.